Study of JK07 in Patients With Chronic Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 282 participants.

Also called NCT06369298

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 282 participants (planned count) (from the registry)
Sponsor
Salubris Biotherapeutics Inc (from the registry)
Registry
  • NCT NCT06369298
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, China, Puerto Rico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06369298. Randomized; triple masking; primary purpose treatment. Start 2024-03-28 (actual); primary completion 2026-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of JK07 in Patients With Chronic Heart Failure
Acronym
RENEU-HF
Intervention (Drug)
JK07
Intervention (Drug)
Placebo
Lead sponsor
Salubris Biotherapeutics Inc (class: industry)

Record details

Record id
cardio:ct-nct06369298
Content hash
459c9ea00f6a892cbac3a5b4148a8db39148c70fab137c6f918691fbd4b6c780